LCTX
Lineage Cell Therapeutics Inc
1.00$
+8.7%
vs. previous close
Closing price · As of: Oct 8, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 41.0% | 38.1% | 42.1% | 39.3% | 35.6% | 45.0% | 44.7% | 48.3% | 47.1% | 52.5% | 51.3% | 49.9% | |
| 29.6% | 35.1% | 40.2% | 28.8% | 28.7% | 40.4% | 42.8% | 46.6% | 45.1% | 36.2% | 32.8% | 35.2% | |
| 38.9% | 35.1% | 40.2% | 37.4% | 33.9% | 42.2% | 42.9% | 46.6% | 45.2% | 49.5% | 48.7% | 47.9% | |
| 0.4% | 0.7% | 0.1% | 0.2% | 0.4% | 0.6% | 0.2% | 0.3% | 0.1% | 1.4% | 0.7% | 0.7% | |
| 10.1% | 10.6% | 9.8% | 10.4% | 11.0% | 9.4% | 9.5% | 11.8% | 11.9% | 9.5% | 9.7% | 10.0% | |
| 43.9% | 46.1% | 42.9% | 45.3% | 48.2% | 41.1% | 41.6% | 34.9% | 35.4% | 28.2% | 28.9% | 29.8% | |
| 37.2% | 38.6% | 34.6% | 34.9% | 32.9% | 32.0% | 30.5% | 48.1% | 76.8% | 61.5% | 51.9% | 43.7% | |
| 15.0% | 17.8% | 15.6% | 14.9% | 14.4% | 12.3% | 11.7% | 11.8% | 10.5% | 10.1% | 7.4% | 7.5% | |
| 0.9% | 0.9% | 1.0% | 1.1% | 1.2% | 1.0% | 1.1% | 1.2% | 1.2% | 0.8% | 0.8% | 0.9% | |
| 2.3% | 2.0% | 2.0% | 2.3% | 1.7% | 1.0% | 1.8% | 1.6% | 1.7% | 2.1% | 5.1% | 1.4% | |
| 64.2% | 62.8% | 66.7% | 66.4% | 68.5% | 69.2% | 70.7% | 53.3% | 24.6% | 39.6% | 49.2% | 57.3% | |
| -358.1% | -381.0% | -360.8% | -386.3% | -414.3% | -356.4% | -364.7% | -482.5% | -521.9% | -414.8% | -430.7% | -442.8% | |
| 164.7% | 170.9% | 168.6% | 183.7% | 195.5% | 176.8% | 202.3% | 251.5% | 255.3% | 204.4% | 238.4% | 246.2% |
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.